-
QTTB Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Q32 Bio (QTTB)
Company Profile
Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.73 mm | 89.73 mm | 89.73 mm | 89.73 mm | 89.73 mm | |
Cash burn (monthly) | 8.81 mm | (no burn) | 6.27 mm | 2.64 mm | (no burn) | |
Cash used (since last report) | 24.68 mm | n/a | 17.57 mm | 7.41 mm | n/a | |
Cash remaining | 65.05 mm | n/a | 72.16 mm | 82.32 mm | n/a | |
Runway (months of cash) | 7.4 | n/a | 11.5 | 31.1 | n/a |
13F holders | Current |
---|---|
Total holders | 55 |
Opened positions | 26 |
Closed positions | 4 |
Increased positions | 13 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 143.43 bn |
Total shares | 9.70 mm |
Total puts | 0.00 |
Total calls | 160.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 2.25 mm | $40.44 bn |
Atlas Venture Life Science Advisors | 2.09 mm | $37.55 bn |
CG The Carlyle Group Inc. | 1.10 mm | $19.20 bn |
Atlas Venture Fund X | 864.26 k | $808.00 k |
Acorn Bioventures | 803.43 k | $751.00 k |
BLK BlackRock | 342.27 k | $6.14 bn |
Arch Venture | 320.48 k | $5.75 bn |
Temasek | 313.94 k | $5.64 bn |
5AM Venture Management | 251.99 k | $4.52 bn |
FMR | 179.64 k | $3.22 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Oct 24 | Shelia M. Violette | Common Stock | Option exercise | Acquire M | No | No | 7.29 | 6,000 | 43.74 k | 23,874 |
15 Oct 24 | Shelia M. Violette | Stock Option Common Stock | Option exercise | Dispose M | No | No | 7.29 | 6,000 | 43.74 k | 32,891 |
11 Oct 24 | Shelia M. Violette | Common Stock | Option exercise | Acquire M | No | No | 3.12 | 4,574 | 14.27 k | 17,874 |
11 Oct 24 | Shelia M. Violette | Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.12 | 4,361 | 13.61 k | 0 |
11 Oct 24 | Shelia M. Violette | Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.12 | 213 | 664.56 | 0 |
8 Oct 24 | Shelia M. Violette | Common Stock | Option exercise | Acquire M | No | No | 3.12 | 13,300 | 41.50 k | 13,300 |
8 Oct 24 | Shelia M. Violette | Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.12 | 13,300 | 41.50 k | 213 |
25 Sep 24 | Sven Ante Lundberg | Stock Option Common Stock | Grant | Acquire A | No | No | 44.4 | 1,316 | 58.43 k | 1,316 |
1 Apr 24 | Grayzel David S. | Stock Option Common Stock | Grant | Acquire A | No | No | 13.42 | 2,569 | 34.48 k | 2,569 |
1 Apr 24 | Isaac Manke | Stock Option Common Stock | Grant | Acquire A | No | No | 13.42 | 2,627 | 35.25 k | 2,627 |